Clinical and Technical Considerations for Brain PET Imaging for Dementia

Area of Science:

• Neurology
• Radiology
• Nuclear Medicine

Background:

• Dementia cases have significantly increased globally.
• Positron Emission Tomography (PET) imaging for dementia has seen major technological and radiopharmaceutical advancements in the last decade.
• The U.S. Food and Drug Administration has approved new PET radiopharmaceuticals for amyloid detection, with tau PET agents in clinical trials.

Purpose of the Study:

• To review the utility of PET imaging in diagnosing various forms of dementia.
• To discuss the commonly used radiopharmaceuticals for dementia PET imaging.
• To provide technical recommendations for performing dementia PET studies.

Main Methods:

• Review of current literature on PET imaging in dementia.
• Discussion of approved and investigational PET radiopharmaceuticals for amyloid and tau.
• Outline of technical considerations for PET scan acquisition and interpretation.

Main Results:

• PET imaging, particularly with novel radiopharmaceuticals, offers improved visualization of key dementia biomarkers like amyloid and tau.
• Several dementia subtypes can be effectively imaged using PET.
• Technical advancements enhance the diagnostic accuracy and clinical utility of PET scans.

Conclusions:

• PET imaging plays a crucial role in the diagnosis and management of dementia.
• The development of specific radiopharmaceuticals for amyloid and tau has revolutionized dementia imaging.
• Standardized technical protocols are essential for reliable and reproducible PET imaging in dementia.